

REFERENCES

- Bajwa S. S., Markland F. S., and Russell F. E. (1980). Fibrinolytic enzyme(s) in western diamondback rattlesnake (*Crotalus atrox*) venom. *Toxicon* 18: 285-90.
- Baramova E. N., Shannon J. D., Bjarnason J. B., and Fox J. W. (1989). Degradation of extracellular matrix proteins by hemorrhagic metalloproteinases. *Arch. Biochem. Biophys.* 275: 63-71.
- Bello C. A., Hermogenes A. L., Magalhaes A., Veiga S. S., Gremski L. H., Richardson M., and Sanchez E. F. (2006). Isolation and biochemical characterization of a fibrinolytic proteinase from *Bothrops leucurus* (white-tailed jararaca) snake venom. *Biochimie* 88: 189-200.
- Bjarnason J. B., and Fox J. W. (1994). Hemorrhagic metalloproteinases from snake venoms. *Pharmacol. Ther.* 62: 325-72.
- Bjarnason J. B., Hamilton D., and Fox J. W. (1988). Studies on the mechanism of hemorrhage production by five proteolytic hemorrhagic toxins from *Crotalus atrox* venom. *Biol Chem Hoppe Seyler* 369 Suppl: 121-9.
- Bode W., Gomis-Ruth F. X., and Stockler W. (1993). Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. *FEBS Lett.* 331: 134-40.

- Bode W., Grams F., Reinemer P., Gomis-Ruth F. X., Baumann U., McKay D. B., and Stocker W. (1996). The metzincin-superfamily of zinc-peptidases. *Adv. Exp. Med. Biol.* 389: 1-11.
- Braud S., Bon C., and Wisner A. (2000). Snake venom proteins acting on hemostasis. *Biochimie* 82: 851-9.
- Burkhart W., Smith G. F., Su J. L., Parikh I., and LeVine H., 3rd (1992). Amino acid sequence determination of ancrod, the thrombin-like alpha-fibrinogenase from the venom of *Akistrodon rhodostoma*. *FEBS Lett.* 297: 297-301.
- Byzova T. V., and Plow E. F. (1997). Networking in the hemostatic system. Integrin alpha_{IIb}beta₃ binds prothrombin and influences its activation. *J. Biol. Chem.* 272: 27183-8.
- Chen T., and Rael E. D. (1997). Purification of M5, a fibrinolytic proteinase from *Crotalus molossus molossus* venom that attacks complement. *Int. J. Biochem Cell Biol.* 29: 789-99.
- Cox J. L., Lee E., Langer A., Armstrong P. W., and Naylor C. D. (1997). Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. *Cmaj* 156: 497-505.

- Daltry J. C., Ponnudurai G., Shin C. K., Tan N. H., Thorpe R. S., and Wuster W. (1996). Electrophoretic profiles and biological activities: intraspecific variation in the venom of the Malayan pit viper (*Calloselasma rhodostoma*). *Toxicon* 34: 67-79.
- Datta G., Dong A., Witt J., and Tu A. T. (1995). Biochemical characterization of basilase, a fibrinolytic enzyme from *Crotalus basiliscus basiliscus*. *Arch. Biochem. Biophys.* 317: 365-73.
- Gatenby P. A. (2004). Controversies in the antiphospholipid syndrome and stroke. *Thromb. Res.* 114: 483-8.
- Guan A. L., Retzios A. D., Henderson G. N., and Markland F. S., Jr. (1991). Purification and characterization of a fibrinolytic enzyme from venom of the southern copperhead snake (*Agkistrodon contortrix contortrix*). *Arch. Biochem. Biophys.* 289: 197-207.
- Hahn B. S., Chang I. M., and Kim Y. S. (1995). Purification and characterization of piscivorase I and II, the fibrinolytic enzymes from eastern cottonmouth moccasin venom (*Agkistrodon piscivorus piscivorus*). *Toxicon* 33: 929-41.
- Hite L. A., Shannon J. D., Bjarnason J. B., and Fox J. W. (1992). Sequence of a cDNA clone encoding the zinc metalloproteinase hemorrhagic toxin e from *Crotalus atrox*: evidence for signal, zymogen, and disintegrin-like structures. *Biochemistry* 31: 6203-11.
- Huang S. Y., and Perez J. C. (1980). Comparative study on hemorrhagic and proteolytic activities of snake venoms. *Toxicon* 18: 421-6.

- Hung C. C., Huang K. F., and Chiou S. H. (1994). Characterization of one novel venom protease with beta-fibrinogenase activity from the Taiwan habu (*Trimeresurus mucrosquamatus*): purification and cDNA sequence analysis. *Biochem. Biophys. Res. Commun.* 205: 1707-15.
- Itoh N., Tanaka N., Mihashi S., and Yamashina I. (1987). Molecular cloning and sequence analysis of cDNA for batroxobin, a thrombin-like snake venom enzyme. *J. Biol. Chem.* 262: 3132-5.
- Lee J. W., and Park W. (2000). cDNA cloning of brevinase, a heterogeneous two-chain fibrinolytic enzyme from *Agkistrodon blomhoffii brevicaudus* snake venom, by serial hybridization-polymerase chain reaction. *Arch. Biochem. Biophys.* 377: 234-40.
- Lee J. W., Seu J. H., Rhee I. K., Jin I., Kawamura Y., and Park W. (1999). Purification and characterization of brevinase, a heterogeneous two-chain fibrinolytic enzyme from the venom of Korean snake, *Agkistrodon blomhoffii brevicaudus*. *Biochem. Biophys. Res. Commun.* 260: 665-70.
- Leonardi A., Aragon-Ortiz F., Gubensek F., and Krizaj I. (1999). Partial primary structure of a fibrinogenase from the venom of the snake *Lachesis stenophrys*. *J. Chromatogr. A* 852: 237-43.
- Loayza S. L., Trikha M., Markland F. S., Riquelme P., and Kuo J. (1994). Resolution of isoforms of natural and recombinant fibrolase, the fibrinolytic enzyme from

- Agkistrodon contortrix contortrix* snake venom, and comparison of their EDTA sensitivities. *J. Chromatogr. B Biomed. Appl.* 662: 227-43.
- Lu Q., Clemetson J. M., and Clemetson K. J. (2005). Snake venoms and hemostasis. *J. Thromb. Haemost.* 3: 1791-9.
- Marin F., Roldan V., and Lip G. Y. (2003). Fibrinolytic function and atrial fibrillation. *Thromb. Res.* 109: 233-40.
- Markland F. S., Friedrichs G. S., Pewitt S. R., and Lucchesi B. R. (1994). Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. *Circulation* 90: 2448-56.
- Markland F. S., Jr. (1976). Crotalase. *Methods Enzymol.* 45: 223-36.
- Markland F. S., Jr. (1998). Snake venom fibrinogenolytic and fibrinolytic enzymes: an updated inventory. Registry of Exogenous Hemostatic Factors of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Thromb. Haemost.* 79: 668-74.
- McKeller M. R., and Perez J. C. (2002). The effects of Western Diamondback Rattlesnake (*Crotalus atrox*) venom on the production of antihemorrhagins and/or antibodies in the Virginia opossum (*Didelphis virginiana*). *Toxicon* 40: 427-39.
- Moreno A. M., Alberola A. G., Tomas J. G., Chavarri M. V., Soria F. C., Sanchez E. M., and Sanchez J. G. (1997). Incidence and prognostic significance of right bundle branch block in patients with acute myocardial infarction receiving thrombolytic therapy. *Int. J. Cardiol.* 61: 135-41.

Omori-Satoh T., Sadahiro S., Ohsaka A., and Murata R. (1972). Purification and characterization of an antihemorrhagic factor in the serum of *Trimeresurus flavoviridis*, a crotalid. *Biochim. Biophys. Acta.* 285: 414-26.

Ouyang C., Hwang L. J., and Huang T. F. (1983). alpha-Fibrinogenase from *Agkistrodon rhodostoma* (Malayan pit viper) snake venom. *Toxicon* 21: 25-33.

Pennica D., Holmes W. E., Kohr W. J., Harkins R. N., Vehar G. A., Ward C. A., Bennett W. F., Yelverton E., Seeburg P. H., Heyneker H. L., Goeddel D. V., and Collen D. (1983). Cloning and expression of human tissue-type plasminogen activator cDNA in *E. coli*. *Nature* 301: 214-21.

Perez J. C., McKeller M. R., Perez J. C., Sanchez E. E., and Ramirez M. S. (2001). An internet database of crotaline venom found in the United States. *Toxicon* 39: 621-32.

Perez J. C., Pichyangkul S., and Garcia V. E. (1979). The resistance of three species of warm-blooded animals to Western diamondback rattlesnake (*Crotalus atrox*) venom. *Toxicon* 17: 601-7.

Pithayanukul P., Laovachirasawan S., Bavovada R., Pakmanee N., and Suttisri R. (2004). Anti-venom potential of butanolic extract of *Eclipta prostrata* against Malayan pit viper venom. *J. Ethnopharmacol.* 90: 347-52.

Pretzer D., Schulteis B. S., Smith C. D., Vander Velde D. G., Mitchell J. W., and Manning M. C. (1993). Fibrolase. A fibrinolytic protein from snake venom. *Pharm. Biotechnol.* 5: 287-314.

- Ramirez M. S., Sanchez E. E., Garcia-Prieto C., Perez J. C., Chapa G. R., McKeller M. R., Ramirez R., and De Anda Y. (1999). Screening for fibrinolytic activity in eight Viperid venoms. *Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol.* 124: 91-8.
- Randolph A., Chamberlain S. H., Chu H. L., Retzios A. D., Markland F. S., Jr., and Masiarz F. R. (1992). Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from *Agkistrodon contortrix contortrix* venom. *Protein Sci.* 1: 590-600.
- Retzios A. D., and Markland F. S. (1994). Fibrinolytic enzymes from the venoms of *Agkistrodon contortrix contortrix* and *Crotalus basiliscus basiliscus*: cleavage site specificity towards the alpha-chain of fibrin. *Thromb. Res.* 74: 355-67.
- Retzios A. D., and Markland F. S., Jr. (1988). A direct-acting fibrinolytic enzyme from the venom of *Agkistrodon contortrix contortrix*: effects on various components of the human blood coagulation and fibrinolysis systems. *Thromb. Res.* 52: 541-52.
- Rodrigues V. M., Soares A. M., Guerra-Sa R., Rodrigues V., Fontes M. R., and Giglio J. R. (2000). Structural and functional characterization of neuwiedase, a nonhemorrhagic fibrin(ogen)olytic metalloprotease from *Bothrops neuwiedi* snake venom. *Arch. Biochem. Biophys.* 381: 213-24.
- Sanchez E. E., Galan J. A., Perez J. C., Rodriguez-Acosta A., Chase P. B., and Perez J. C. (2003a). The efficacy of two antivenoms against the venom of North American snakes. *Toxicon* 41: 357-65.

- Sanchez E. E., Garcia C., Perez J. C., and De La Zerda S. J. (1998). The detection of hemorrhagic proteins in snake venoms using monoclonal antibodies against Virginia opossum (*Didelphis virginiana*) serum. *Toxicon* 36: 1451-9.
- Sanchez E. E., Soliz L. A., Ramirez M. S., and Perez J. C. (2001). Partial characterization of a basic protein from *Crotalus molossus molossus* (northern blacktail rattlesnake) venom and production of a monoclonal antibody. *Toxicon* 39: 523-37.
- Sanchez E. F., Costa M. I., Chavez-Olortegui C., Assakura M. T., Mandelbaum F. R., and Diniz C. R. (1995). Characterization of a hemorrhagic factor, LHF-I, isolated from the bushmaster snake (*Lachesis muta muta*) venom. *Toxicon* 33: 1653-67.
- Sanchez E. F., Magalhes A., Mandelbaum F. R., and Diniz C. R. (1991). Purification and characterization of the hemorrhagic factor II from the venom of the Bushmaster snake (*Lachesis muta muta*). *Biochim. Biophys. Acta* 1074: 347-56.
- Sanchez E. F., Souza C. T., Bello C. A., Richardson M., Oliveira E. B., and Magalhaes A. (2003b). Resolution of isoforms of metalloproteinase from bushmaster snake venom. *Toxicon* 41: 1021-31.
- Siigur J., Samel M., Tonismagi K., Subbi J., Siigur E., and Tu A. T. (1998). Biochemical characterization of lebetase, a direct-acting fibrinolytic enzyme from *Vipera lebetina* snake venom. *Thromb. Res.* 90: 39-49.
- Stocker W., and Bode W. (1995). Structural features of a superfamily of zinc-endopeptidases: the metzincins. *Curr. Opin. Struct. Biol.* 5: 383-90.

- Stocker W., Gomis-Ruth F. X., Bode W., and Zwilling R. (1993). Implications of the three-dimensional structure of astacin for the structure and function of the astacin family of zinc-endopeptidases. *Eur. J. Biochem.* 214: 215-31.
- Swenson S., and Markland F. S., Jr. (2005). Snake venom fibrin(ogen)olytic enzymes. *Toxicon* 45: 1021-39.
- Terada S., Hori J., Fujimura S., and Kimoto E. (1999). Purification and amino acid sequence of brevilysin L6, a non-hemorrhagic metalloprotease from *Agkistrodon halys brevicaudus* venom. *J. Biochem. (Tokyo)* 125: 64-9.
- Toombs C. F. (2001a). Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis. *Haemostasis* 31: 141-7.
- Toombs C. F. (2001b). New directions in thrombolytic therapy. *Curr. Opin. Pharmacol.* 1: 164-8.
- Viravan C., Looareesuwan S., Kosakarn W., Wuthiekanun V., McCarthy C. J., Stimson A. F., Bunnag D., Harinasuta T., and Warrell D. A. (1992). A national hospital-based survey of snakes responsible for bites in Thailand. *Trans. R. Soc. Trop. Med. Hyg.* 86: 100-6.
- White H. D., Aylward P. E., Frey M. J., Adgey A. A., Nair R., Hillis W. S., Shalev Y., Brown M. A., French J. K., Collins R., Maraganore J., and Adelman B. (1997). Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO).

- Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. *Circulation* 96: 2155-61.
- Willis T. W., and Tu A. T. (1988). Purification and biochemical characterization of atroxase, a nonhemorrhagic fibrinolytic protease from western diamondback rattlesnake venom. *Biochemistry* 27: 4769-77.
- Xiuxia L., Jiashu C., Yingna Z., Pengxin Q., and Guangmei Y. (2001). Purification and biochemical characterization of F II(a), a fibrinolytic enzyme from *Agkistrodon acutus* venom. *Toxicon* 39: 1133-9.
- Zhang Y., Wisner A., Maroun R. C., Choumet V., Xiong Y., and Bon C. (1997). *Trimeresurus stejnegeri* snake venom plasminogen activator. Site-directed mutagenesis and molecular modeling. *J. Biol. Chem.* 272: 20531-7.
- Zhang Y., Wisner A., Xiong Y., and Bon C. (1995). A novel plasminogen activator from snake venom. Purification, characterization, and molecular cloning. *J. Biol. Chem.* 270: 10246-55.
- Zhang Y. L., Hervio L., Strandberg L., and Madison E. L. (1999). Distinct contributions of residue 192 to the specificity of coagulation and fibrinolytic serine proteases. *J. Biol. Chem.* 274: 7153-6.

APPENDICES

[New FindPept Search](#)[PeptideMass](#)[FindMod](#)[GlycoMod](#)[Biograph](#)

FindPept documentation
Mass values and considered PTMs

Matching peptides for unspecific cleavage:

User mass	DB mass	Δmass (daltons)	peptide	position modifications	missed cleavages
118.458	118.086	-0.371	V(I)	1-1	0
118.458	118.086	-0.371	(L)V(V)	16-16	0
118.458	118.086	-0.371	(V)V(A)	17-17	0
118.458	118.086	-0.371	(A)V(Y)	19-19	0
118.458	118.086	-0.371	(G)V(L)	32-32	0
118.458	118.086	-0.371	(W)V(I)	40-40	0
118.458	118.086	-0.371	(L)V(F)	54-54	0
118.458	118.086	-0.371	(P)V(N)	99-99	0
118.458	118.086	-0.371	(I)V(G)	117-117	0
118.458	118.086	-0.371	(R)V(M)	123-123	0
118.458	118.086	-0.371	(D)V(L)	135-135	0
118.458	118.086	-0.371	(R)V(L)	167-167	0
118.458	118.086	-0.371	(I)V(A)	198-198	0
118.458	118.086	-0.371	(W)V(N)	224-224	0
118.458	118.086	-0.371	(N)V(I)	227-227	0
203.685	204.098	0.412	(C)AN(I)	144-145	0
203.685	204.098	0.412	(G)NA(T)	231-232	0
203.685	204.134	0.449	(K)KG(R)	164-165	0
230.985	231.170	0.185	VI(G)	1-2	0
230.985	231.170	0.185	(G)VL(L)	32-33	0
230.985	231.170	0.185	(W)VI(T)	40-41	0
230.985	231.170	0.185	(D)VL(S)	135-136	0
230.985	231.170	0.185	(R)VL(C)	167-168	0
230.985	231.170	0.185	(N)VI(A)	227-228	0
230.985	231.170	0.185	(F)LV(V)	15-16	0
230.985	231.170	0.185	(N)LV(F)	53-54	0
230.985	231.170	0.185	(P)IV(G)	116-117	0
230.985	231.170	0.185	(G)IV(A)	197-198	0
245.650	245.186	-0.464	(V)LL(I)	33-34	0
245.650	245.186	-0.464	(L)LI(H)	34-35	0
245.650	245.186	-0.464	(M)LI(R)	92-93	0
245.650	245.186	-0.464	(P)LI(C)	188-189	0
245.650	246.145	0.494	(V)IGG(D)	2-4	0

245.650	246.145	0.494	(C)NI(N)	8-9	0
245.650	246.145	0.494	(M)NL(V)	52-53	0
245.650	246.145	0.494	(A)NI(N)	145-146	0
245.650	246.145	0.494	(I)NL(H)	147-148	0
245.650	246.145	0.494	(N)IN(E)	9-10	0
245.650	246.145	0.494	(R)LN(K)	95-96	0
245.650	246.145	0.494	(S)IN(R)	129-130	0
245.650	246.145	0.494	(N)IN(L)	146-147	0
248.706	249.072	0.365	(F)DD(E)	65-66	0
248.706	249.127	0.420	(R)VM(G)	123-124	0
250.036	250.086	0.049	(L)CAG(D)	169-171	0
279.025	279.134	0.108	(R)YP(K)	71-72	0
279.025	279.170	0.145	(R)FL(V)	14-15	0
279.025	279.170	0.145	(T)FI(C)	27-28	0
279.025	279.170	0.145	(G)LF(R)	157-158	0
327.604	327.166	-0.437	(S)NPP(I)	113-115	0
327.604	327.166	-0.437	(G)PNP(C)	202-204	0
334.884	335.120	0.235	(S)DSGG(P)	183-186	0
334.884	335.120	0.235	(C)NSD(S)	181-183	0
334.884	335.138	0.254	(I)CGGV(L)	29-32	0
353.656	354.115	0.459	(F)TMC(H)	152-154	0
353.656	354.148	0.492	(V)FGM(H)	55-57	0
356.602	356.156	-0.445	(T)AEH(C)	43-45	0
361.562	361.172	-0.390	(V)IGGD(E)	2-5	0
364.117	364.165	0.047	(R)CNK(T)	79-81	0
371.558	371.167	-0.390	(G)TNH(T)	23-25	0
371.558	371.167	-0.390	(T)NHT(F)	24-26	0
374.796	375.181	0.384	(E)PRC(A)	141-143	0
374.796	375.187	0.391	(C)AGDL(R)	170-173	0
374.796	375.187	0.391	(N)INE(R)	9-11	0
374.796	375.206	0.410	(K)MPK(K)	161-163	0
374.796	375.206	0.410	(R)KMP(K)	160-162	0
374.796	375.224	0.427	(P)IVGS(D)	116-119	0
376.236	376.171	-0.064	(D)EDI(M)	88-90	0
376.236	376.226	-0.009	(D)IML(I)	90-92	0
376.236	376.226	-0.009	(I)MLI(R)	91-93	0
380.229	380.218	-0.011	(H)TFI(C)	26-28	0
383.307	383.204	-0.103	(I)NLH(N)	147-149	0
383.307	383.204	-0.103	(N)LHN(F)	148-150	0
387.660	387.224	-0.436	(I)APLS(L)	106-109	0
387.660	387.260	-0.399	(L)VVAV(Y)	16-19	0

387.660	387.271	-0.388	(G)RVL(C)	166-168	0
387.660	388.129	0.468	(A)EHC(A)	44-46	0
400.901	401.214	0.313	(D)EPR(C)	140-142	0
400.901	401.276	0.374	(F)LVVA(V)	15-18	0
400.901	401.276	0.374	(G)GVLL(I)	31-34	0
400.901	401.287	0.386	(M)LIR(L)	92-94	0
400.901	401.287	0.386	(L)IIRL(N)	93-95	0
402.559	402.246	-0.313	(I)VARG(P)	198-201	0
402.559	402.246	-0.313	(I)RLN(K)	94-96	0
402.559	402.246	-0.313	(S)INR(R)	129-131	0
402.559	402.257	-0.301	(C)ARR(R)	47-49	0
406.877	407.156	0.279	(T)SWD(E)	85-87	0
406.877	407.159	0.282	(A)TCSP	233-236	0
406.877	407.229	0.351	(R)YPK(K)	71-73	0
409.629	409.169	-0.460	(F)MRC(N)	77-79	0
409.629	409.208	-0.420	(E)KFD(D)	63-65	0
418.105	418.175	0.070	(N)PCAQ(P)	204-207	0
418.105	418.175	0.070	(P)CAQP(N)	205-208	0
418.105	418.204	0.099	(I)NER(R)	10-12	0
418.105	418.208	0.103	(D)WVN(N)	223-225	0
422.354	422.152	-0.202	(N)SDSGG(P)	182-186	0
422.354	422.152	-0.202	(C)NSDS(G)	181-184	0
423.605	423.118	-0.486	(G)GDEC(N)	4-7	0
423.605	423.224	-0.381	(S)EKF(D)	62-64	0
432.182	432.172	-0.009	(S)DSGGP(L)	183-187	0
432.182	432.220	0.038	(E)QER(Y)	68-70	0
434.284	434.254	-0.029	(F)RKM(P)	159-161	0
446.422	446.218	-0.204	(E)PRCA(N)	141-144	0
446.422	446.247	-0.175	(G)RRD(S)	176-178	0
450.763	450.282	-0.480	(L)FRK(M)	158-160	0
450.763	451.255	0.492	(V)VAVY(E)	17-20	0
463.248	463.178	-0.069	(V)NNSE(H)	100-103	0
463.248	463.197	-0.051	(E)CNIN(E)	7-10	0
463.248	463.208	-0.039	(P)RCAN(I)	142-145	0
463.248	463.255	0.007	(K)PALY(T)	211-214	0
465.332	465.176	-0.155	(A)GNATC(S)	230-234	0
465.332	465.213	-0.119	(R)CNKT(R)	79-82	0
467.302	467.214	-0.088	(A)VYEG(T)	19-22	0
467.302	467.225	-0.077	(Q)ERY(P)	69-71	0
467.302	467.250	-0.051	(P)ALYT(S)	212-215	0
469.097	469.193	0.095	(V)YEGT(N)	20-23	0

593.466	593.260	-0.206	(P)IVGSDC(R)	116-121	0
599.887	600.237	0.350	(V)NNSEH(I)	100-104	0
604.072	604.337	0.265	(E)DIMLI(R)	89-93	0
611.514	611.326	-0.188	(V)ARGPNP(C)	199-204	0
622.750	623.245	0.495	(I)AGNATCS(P)	229-235	0
635.562	635.215	-0.346	(F)DDEQE(R)	65-69	0
635.562	635.288	-0.273	(I)DVLSSD(E)	134-139	0
640.563	640.188	-0.375	(R)DSCNSD(S)	178-183	0
642.139	642.325	0.186	(E)HCARR(R)	45-49	0
644.023	644.315	0.292	(I)NLHNFT(T)	147-151	0
647.895	647.413	-0.482	(R)FLVVAV(Y)	14-19	0
647.895	648.329	0.433	(C)RVMGW(G)	122-126	0
650.241	650.245	0.003	(G)GDECNI(N)	4-9	0
650.241	650.297	0.055	(V)MGWGSI(N)	124-129	0
650.241	650.326	0.084	(K)TRTSW(D)	82-86	0
652.353	652.389	0.035	(L)HGIVAR(G)	195-200	0
654.470	654.357	-0.113	(A)QPNKPA(L)	207-212	0
654.470	654.357	-0.113	(C)AQPNKP(A)	206-211	0
656.948	657.427	0.478	(D)LRGRR(D)	173-177	0
661.436	661.280	-0.156	(F)TMCHGL(F)	152-157	0
661.436	661.367	-0.068	(H)CARRR(M)	46-50	0
666.851	667.320	0.468	(I)HPEWV(I)	36-40	0
670.277	670.280	0.002	(Y)FMRCN(K)	76-80	0
670.277	670.315	0.038	(N)NSEHIA(P)	101-106	0
674.583	674.391	-0.192	(F)ICGGVLL(I)	28-34	0
674.583	674.391	-0.192	(I)CGGVLL(H)	29-35	0
676.161	676.290	0.128	(D)DEQER(Y)	66-70	0
676.161	676.305	0.143	(E)GTNHTF(I)	22-27	0
679.088	679.366	0.278	(L)VVAVYE(G)	16-21	0
679.088	679.377	0.289	(S)EHIAPL(S)	103-108	0
681.153	681.262	0.109	(R)RDSCNS(D)	177-182	0
681.153	681.335	0.182	(L)IHPEW(V)	35-39	0
681.153	681.368	0.214	(C)ANINLH(N)	144-149	0
683.564	683.372	-0.191	(S)NPPIVGS(D)	113-119	0
683.564	683.372	-0.191	(P)SNPPIVG(S)	112-118	0
686.609	686.293	-0.316	(R)GPNPCAQ(P)	201-207	0
686.609	686.304	-0.305	(T)AEHCAR(R)	43-48	0
686.609	686.383	-0.225	(W)VNNVIAG(N)	224-230	0
689.838	689.388	-0.450	(R)RRMNL(V)	49-53	0
689.838	689.399	-0.439	(C)ARRRM(N)	47-51	0
689.838	690.288	0.449	(S)DEPRCA(N)	139-144	0

689.838	690.305	0.467	(L)SSDEPR(C)	137-142	0
689.838	690.313	0.474	(P)PIVGSDC(R)	115-121	0
689.838	690.335	0.497	(P)RCANIN(L)	142-147	0
695.942	696.338	0.396	(H)TFICGGV(L)	26-32	0
698.279	698.310	0.031	(C)NEELHG(I)	191-196	0
698.279	698.387	0.108	(R)YPKKY(F)	71-75	0
701.915	702.401	0.485	(W)GSINRR(I)	127-132	0
701.915	702.414	0.499	(R)RIDVLS(S)	132-137	0
722.030	722.361	0.331	(R)CNKTRT(S)	79-84	0
724.050	724.326	0.276	(D)EQQUERY(P)	67-71	0
724.050	724.374	0.323	(A)NINLHN(F)	145-150	0
731.173	731.299	0.126	(I)YDYRD(W)	218-222	0
732.842	732.361	-0.481	(M)CHGLFR(K)	154-159	0
732.842	732.367	-0.474	(G)TNHTFI(C)	23-28	0
732.842	732.379	-0.463	(G)WGSINR(R)	126-131	0
732.842	732.405	-0.437	(A)RRRMN(L)	48-52	0
734.499	734.329	-0.170	(N)HTFICGG(V)	25-31	0
734.499	734.329	-0.169	(T)NHTFIC(G)	24-29	0
736.116	736.257	0.140	(S)CNSDSGGP(L)	180-187	0
736.116	736.329	0.213	(V)IAGNATCS(P)	228-235	0
736.116	736.388	0.271	(L)VVAVYEG(T)	16-22	0
738.390	738.357	-0.033	(D)YRDWV(N)	220-224	0
738.390	738.367	-0.023	(V)VAVYEGT(N)	17-23	0
738.390	738.414	0.024	(E)ELHGIVA(R)	193-199	0
745.649	745.355	-0.294	(G)GPLICNE(E)	186-192	0
745.649	745.363	-0.286	(I)NLHNFT(M)	147-152	0
745.649	745.373	-0.276	(N)SDSGGPLI(C)	182-189	0
747.119	747.382	0.262	(V)LCAGDLR(G)	168-174	0
749.363	749.361	-0.001	(P)IVGSDCR(V)	116-122	0
749.363	749.365	0.002	(R)VMGWGSI(N)	123-129	0
751.370	751.338	-0.032	(D)CRVMGW(G)	121-126	0
751.370	751.428	0.058	(H)GLFRKM(P)	156-161	0
764.791	764.310	-0.481	(T)SWDEDI(M)	85-90	0
764.791	764.331	-0.460	(I)DVLSSDE(P)	134-140	0
764.791	764.340	-0.451	(V)MGWGSIN(R)	124-130	0
764.791	764.419	-0.372	(K)PALYTSI(Y)	211-217	0
766.531	766.409	-0.121	(N)SEHIAPL(S)	102-108	0
766.531	766.409	-0.121	(S)EHIAPLS(L)	103-109	0
770.460	770.404	-0.055	(P)SNPPIVGS(D)	112-119	0
776.820	777.320	0.499	(S)SDEPRCA(N)	138-144	0
785.775	785.372	-0.402	(V)ARGPNPCA(Q)	199-206	0

787.992	787.497	-0.494	(F)RKMPKK(G)	159-164	0
787.992	788.456	0.463	(R)RRMNLV(F)	49-54	0
795.928	796.289	0.360	(R)RDSCNSD(S)	177-183	0
795.928	796.358	0.430	(K)PVNNSEH(I)	98-104	0
795.928	796.420	0.491	(N)EELHGIV(A)	192-198	0
797.397	797.477	0.079	(H)IAPSLPS(N)	105-112	0
797.397	797.536	0.138	(M)PKKGRVL(C)	162-168	0
803.419	803.379	-0.039	(Y)RDWVNN(V)	221-226	0
803.419	803.389	-0.029	(V)LSSDEPR(C)	136-142	0
803.419	803.419	0.000	(P)RCANINL(H)	142-148	0
803.419	803.442	0.022	(C)ARRRMN(L)	47-52	0
803.419	803.456	0.036	(K)KGRVLCAG(D)	164-171	0
803.419	803.492	0.072	(P)KKGRVLC(A)	163-169	0
803.419	803.514	0.094	(R)RFLVVAV(Y)	13-19	0
806.441	806.335	-0.106	VIGGDECN(I)	1-8	0
806.441	806.441	0.000	(P)NKPALYT(S)	209-215	0
806.441	806.463	0.022	(L)HGIVARGP(N)	195-202	0
806.441	806.471	0.029	(L)FRKMPK(K)	158-163	0
829.266	829.475	0.209	(A)GDLRGRR(D)	171-177	0
833.202	833.343	0.141	(K)YFMRCN(K)	75-80	0
833.202	833.382	0.180	(V)IAGNATCSP	228-236	0
833.202	833.397	0.195	(N)HTFICGGV(L)	25-32	0
833.202	833.407	0.205	(P)LICNEEL(H)	188-194	0
835.666	835.377	-0.289	(G)TNHTFIC(G)	23-29	0
835.666	835.398	-0.268	(N)VIAGNATCS(P)	227-235	0
839.941	839.546	-0.394	(L)IRLNKPV(N)	93-99	0
839.941	840.367	0.425	(G)PNPCAQP(K)	202-209	0
852.435	852.400	-0.035	(D)YRDWVN(N)	220-225	0
852.435	852.410	-0.025	(V)VAVYEGTN(H)	17-24	0
854.632	854.419	-0.213	(N)PCAQP(K)	204-211	0
854.632	854.488	-0.143	(E)RYPKKY(F)	70-75	0
909.243	909.442	0.199	(K)PVNNSEH(I)	98-105	0
909.243	909.479	0.235	(H)RKSEKFD(D)	59-65	0
914.633	914.404	-0.229	(L)CNEELHG(I)	189-196	0
914.633	914.404	-0.229	(I)CNEELHGI(V)	190-197	0
917.588	917.379	-0.209	(I)YDYRDW(V)	218-223	0
917.588	917.415	-0.173	(S)DEPRCANI(N)	139-146	0
917.588	917.436	-0.151	(Y)TSIYDYR(D)	215-221	0
919.598	919.419	-0.179	VIGGDECNI(N)	1-9	0
919.598	919.547	-0.050	(E)LHGIVARGP(N)	194-202	0
919.598	919.555	-0.043	(G)LFRKMPK(K)	157-163	0

921.599	921.402	-0.196	(S)WDEDIML(I)	86-92	0
921.599	921.504	-0.095	(A)PLSLPSNPP(I)	107-115	0
923.936	923.520	-0.416	(L)SLPSNPPIV(G)	109-117	0
923.936	924.399	0.462	(L)YTSIYDY(R)	214-220	0
926.241	926.488	0.246	(G)IVARGPNPC(A)	197-205	0
928.739	928.576	-0.162	(K)MPKKGRVL(C)	161-168	0
941.007	941.487	0.480	(P)CAQPNKPAL(Y)	205-213	0
942.512	942.479	-0.032	(C)ANINLHNF(T)	144-151	0
948.883	948.443	-0.440	(R)MNLVFGMH(R)	51-58	0
948.883	948.501	-0.382	(C)NINERRF(L)	8-14	0
948.883	948.526	-0.356	(E)QERYPKK(Y)	68-74	0
950.827	950.352	-0.475	(I)GGDECNINE(R)	3-11	0
950.827	950.519	-0.307	(F)LVVAVYEGT(N)	15-23	0
952.356	952.390	0.034	(G)RRDSCNSD(S)	176-183	0
952.356	952.489	0.132	(I)HPEWVITA(E)	36-43	0
952.356	952.630	0.274	(M)LIRLNKPV(N)	92-99	0
961.996	961.504	-0.492	(L)VFGMHRKS(E)	54-61	0
961.996	962.425	0.428	(N)SDSGGPLICN(E)	182-191	0
961.996	962.425	0.428	(S)CNSDSGGPLI(C)	180-189	0
961.996	962.425	0.428	(C)NSDSGGPLIC(N)	181-190	0
961.996	962.495	0.498	(D)LRGRRDSC(N)	173-180	0
964.330	964.449	0.119	(F)TMCHGLFR(K)	152-159	0
966.144	966.443	0.298	(D)YRDWVNN(V)	220-226	0
966.144	966.525	0.381	(N)SEHIAPSL(P)	102-110	0
966.144	966.577	0.433	(R)RFLVVAVY(E)	13-20	0
967.579	967.427	-0.152	(Y)DYRDWVN(N)	219-225	0
967.579	967.484	-0.094	(N)NSEHIAPLS(L)	101-109	0
967.579	967.485	-0.093	(R)RMNLVFGM(H)	50-57	0
969.157	969.534	0.376	(Y)PKKYFMR(C)	72-78	0
971.775	971.582	-0.193	(M)PKKGRVLCA(G)	162-170	0
976.604	976.452	-0.152	(V)NNVIAGNATC(S)	225-234	0
976.604	976.496	-0.107	(R)YPKKYFM(R)	71-77	0
976.604	976.546	-0.057	(S)EHIAPSLP(S)	103-111	0
976.604	976.576	-0.027	(H)GLFRKMPK(K)	156-163	0
977.865	977.436	-0.429	(V)LSSDEPRCA(N)	136-144	0
982.214	982.484	0.269	(L)PSNPPIVGSD(C)	111-120	0
984.059	984.478	0.419	(P)EWVITAEH(C)	38-45	0
985.281	985.540	0.258	(C)HGLFRKMP(K)	155-162	0
988.219	988.440	0.221	(P)SNPPIVGSDC(R)	112-121	0
990.286	990.525	0.239	(Q)PNKPALYTS(I)	208-216	0
998.432	998.506	0.074	(T)AEHCARRR(M)	43-50	0

998.432	998.611	0.178	(S)INRRIDVL(S)	129-136	0
1001.042	1000.620	-0.422	(F)RKMPKKGR(V)	159-166	0
1001.042	1000.634	-0.408	(D)IMLIRLNK(P)	90-97	0
1001.042	1001.541	0.499	(C)AQPNKPALY(T)	206-214	0
1004.750	1004.435	-0.314	(S)DSGGPLICNE(E)	183-192	0
1004.750	1004.447	-0.303	(S)SDEPRCANI(N)	138-146	0
1004.750	1004.508	-0.241	(W)DEDIMLIR(L)	87-94	0
1010.528	1010.418	-0.109	(V)GSDCRVMGW(G)	118-126	0
1010.528	1010.418	-0.109	(G)SDCRVMGWG(S)	119-127	0
1010.528	1010.418	-0.109	(S)DCRVMGWGS(I)	120-128	0
1010.528	1010.484	-0.044	(V)ARGPNPCAQP(N)	199-208	0
1013.306	1013.472	0.166	(I)CNEELHGIV(A)	190-198	0
1016.088	1015.594	-0.493	(C)ARRRMNLV(F)	47-54	0
1016.088	1016.447	0.359	(I)YDYRDWV(N)	218-224	0

Peptides are displayed with the adjoining residues before cleavage greyed out and in parentheses.

Unmatched masses:

11.370
 21.382
 29.998
 35.814
 38.528
 41.135
 55.579
 57.842
 66.422
 68.531
 70.556
 74.623
 80.786
 82.882
 93.177
 134.850
 151.340
 157.559
 193.817
 200.368
 227.615
 238.496
 242.804
 265.954

268.046
298.730
309.154
325.594
354.872
395.238
453.798
470.631
522.331
527.869
566.944
577.922
586.024
668.354
672.344
827.184
831.225

Submit non-matching masses to [FindMod](#) [GlycoMod](#)



[ExPASy Home page](#)

[Site Map](#)

[Search ExPASy](#)

[Contact us](#)

[Proteomics tools](#)

[Swiss-Prot](#)

SWISS MODEL WORKSPACE

[Workspace] [Modelling] [Tools]

[Repository] [General Info] [Links] [Help]

[login]

Workunit: P00237B Title:

Go to: [Template Selection] [Alignment] [Modelling Log] [Evaluation]

Print/Save this page as

Model Details: ☰ Segment 1




Model info:

modelled residue range: 1 to 236
based on template 2a1qA (1.54 Å)
Sequence Identity [%]: 53
Evalue: 1.52e-66

display model: as pdb - as DeepView project
download model: as pdb - as Deepview project - as text

Alignment

TARGET 2aiqA	1 16	VIGGDECN INERRFLVVA VYEGTNHTFI CGGVLLIHP E WVITAEHCA viggdecn inehrflal- vyangs---l cggtl-ing e wvltarhcd
TARGET 2aiqA		SSS SSSSS S SSSS S SSSS SSS SSSS SSS S S SSSSS S S SSSS
TARGET 2aiqA	49 62	RRMNLVFGMH RKSEKFDEQ ERYP-KKYFM RCNKTRTSWD EDIMLIRLN gnmriylgmh nlkvlnkdal rrfpkkeyfc lntrndtiwd kdimlirlnr
TARGET 2aiqA		SSSS S SS SSSSS SSSS S SSSSSSSSS SSSSSSS



Modelling log [top]

```

3.70 (SP3)
Loading Template: 2aiqA.pdb
Loading Raw Sequence
Aligning Raw Sequence
Refining Raw Sequence Alignment
ProModII: doing simple assignment of backbone
ProModII: adding blocking groups
Adding Missing Sidechains
AddPolar H
BuildDeleletedLoopsModel

```

TARGET 2aiqA	98 111	PVNNESEHIAP LSLPSNPPIV GSDCRVMGWG SINRRIDVLS SDEPRCANIN pvrnsahiap lslopsnppsv gsvcrimgwg titspnatlp -dvphecanin
TARGET 2aiqA		sssssss sssssss
TARGET 2aiqA	148 162	LHNFTMCHGL FRKMPKKGRV LCAGDLRGRR DSCNSDGGP LICNEELHGI ildyavcqaaykbla--att lcagileggk dtckgdsggp licngqfqgi
TARGET 2aiqA		ss hhhhhh ss ssss ss sss sssss ss hhhhhh ss ssss ss sss sssss
TARGET 2aiqA	198 213	VARGPNPCAQ PNKPALYTSI YDYRDWVNNV IAGN--ATCS P lsvggnpcqaq prkpgiytkv fdytdwiqsi isgntdatcp p-
TARGET 2aiqA		ss ssssss h h hh h ss ssssss h hhhhh h

Anolea / Gromos / Verify3D [top]

 anolea: on off gromos: on off verify3d: on off show

[ExPASy Home page](#)[Site Map](#)[Search ExPASy](#)[Contact us](#)[PROSITE](#)Search

for



ScanProsite Results Viewer

[Home](#) [ScanProsite](#) [ProRule](#) [Documents](#) [Downloads](#) [Links](#)

This view shows ScanProsite results together with ProRule-based predicted intra-domain features (help).

[show hits of frequently occurring signatures](#)

Hits for all PROSITE (release 20.0) motifs on sequence USERSEQ1 :

found: 17 hits in 1 sequence

USERSEQ1 (236 aa)

```
VIGGDECNINERRFLVVAVYEGTNHTFICGGVLLIHPEWVITAECARRRMNLVFGMHRKSEKFDD
EQERTPKKYFMRCNKTRTSWDEDIMLIRLNKPVNNSSEHIAPLSLP-SNPIVGSDCRVMGWGSINRR
IDVLSSDEPRCANINLHNFTMCAGDLFRKMPKGRVLCAGDLRGRDSCNSDGGPLICNEELHGV
ARGPNPCAQPNCAPALYTSIYDYRDWVNNVIAGRATCSP
```

ruler: 1 100 200 300 400 500 600 700 800 900 1000

hits by profiles: [1 hit (by 1 profile) on 1 sequence]

Hits by PS50240 **TRYPSIN_DOM** Serine proteases, trypsin domain profile :

USERSEQ1 (236 aa)

1 - 229: score = 27.296

```
VIGGDECNINERRFLVVAVYEGtnHTFICGGVLLIHPEWVITAEC----ARRRMNLVF
GMHRKSEKFDDQEERTPKKYFMRCNKTRTSWDEDIMLIRLNKPVNNSSEHIAPLSLP--SN
PPIVGSDCRVMGWGSINRRIDVLSSDEPRCANINLHNFTMCAGDLFRKMPKGRVLCAGDL
RGRDSCNSDGGPLIC---NEELHGVARGpNPQCAQPNCAPALYTSIYDYRDWVNNVIA
```

Predicted features:

DISULFID	29	46	By similarity	[condition: C-x*-C]	
ACT_SITE	45		Charge relay system (By similarity)	[condition: H]	[group: 1]
ACT_SITE	89		Charge relay system (By similarity)	[condition: D]	[group: 1]
DISULFID	121	190	By similarity	[condition: C-x*-C]	
DISULFID	154	169	By similarity	[condition: C-x*-C]	
DISULFID	180	205	By similarity	[condition: C-x*-C]	
ACT_SITE	184		Charge relay system (By similarity)	[condition: S]	[group: 1]

hits by patterns with a high probability of occurrence or by user-defined patterns: [16 hits (by 7 distinct

patterns) on 1 sequence]

USERSEQ1  (236 aa)

PS00008 **MYRISTYL** *N-myristoylation site*:

3 - 8: GGdeCN
 22 - 27: GTnhTP
 230 - 235: GNatCS

PS00001 **ASN_GLYCOSYLATION** *N-glycosylation site*:

24 - 27: NHTF
 80 - 83: NKTR
 100 - 103: NNSE
 150 - 153: NFTH
 231 - 234: NATC

PS00005 **PKC_PHOSPHO_SITE** *Protein kinase C phosphorylation site*:

61 - 63: SeK

PS00007 **TYR_PHOSPHO_SITE** *Tyrosine kinase phosphorylation site*:

63 - 71: KfddEgerY

PS00006 **CK2_PHOSPHO_SITE** *Casein kinase II phosphorylation site*:

84 - 87: TawD
 85 - 88: SwdE
 137 - 140: SedE
 216 - 219: SiyD

PS00009 **AMIDATION** *Amidation site*:

174 - 177: rGRR

PS00004 **CAMP_PHOSPHO_SITE** *cAMP- and cGMP-dependent protein kinase phosphorylation site*:

176 - 179: RRds

Legend:

	♦	—	♦
disulfide bridge	active site	other 'ranges'	other sites

horizontal scaling: 0.6
do not show text labels:
do not show sites in hits:
do not show ranges in hits:

[redisplay](#)

 [ExPASy Home page](#)

[Site Map](#)

[Search ExPASy](#)

[Contact us](#)

[PROSITE](#)

BIOGRAPHY

Mr. Piboon Pornmanee was born on March 20, 1975 in Phattalung province, Thailand. He graduated with a Bachelor's Degree in Medical technology from Chulalongkorn University in 1997, Master's Degree in Biotechnology from Chulalongkorn University in 2001 and continued his Ph.D study in Biotechnology Program in the Faculty of Science Chulalongkorn University and complete the program in 2007.